Jon Napitupulu

Scilex Holding Company (Nasdaq: SCLX) will present a post-hoc analysis of the C.L.E.A.R. trial at the 27th Annual Meeting...

4D Molecular Therapeutics (4DMT) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its product 4D-150,...

Design Therapeutics announced positive Phase 1 trial data for DT-168, an eye drop formulated to treat Fuchs endothelial corneal...

Anavex Life Sciences Corp. has completed enrollment in its Phase 2 clinical trial (ANAVEX3-71-SZ-001) of ANAVEX®3-71 for schizophrenia treatment....

Bio-Path Holdings announced positive preclinical results for BP1001-A, a potential obesity and Type 2 diabetes treatment. The drug candidate...

Biosplice Therapeutics has initiated a Phase 2 clinical trial of its CLK/DYRK kinase inhibitor, cirtuvivint, in patients with advanced...

OBI Pharma, a clinical-stage oncology company, received FDA clearance for an Investigational New Drug (IND) application for OBI-902, a...

Nxera Pharma’s partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist,...

A new study in Cancer Diagnosis & Prognosis shows that Castle Biosciences’ DecisionDx–Melanoma test outperforms current standards for identifying...

The American College of Rheumatology (ACR) updated its lupus nephritis (LN) treatment guidelines, emphasizing triple therapy with Benlysta or...